<PAPER><mode2 name='PMC4655489' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Alzheimers Res Ther</journal-id><journal-id journal-id-type='iso-abbrev'>Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type='epub'>1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>4655489</article-id><article-id pub-id-type='publisher-id'>155</article-id><article-id pub-id-type='doi'>10.1186/s13195-015-0155-9</article-id><article-categories><subj-group subj-group-type='heading'><subject>Research</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer’s disease</s></article-title></title-group><contrib-group><contrib equal-contrib='yes' contrib-type='author'><name><surname>Cheng</surname><given-names>Yu-Wen</given-names></name><address><email>yuwencheng610@gmail.com</email></address><xref rid='Aff1' ref-type='aff'></xref></contrib><contrib equal-contrib='yes' contrib-type='author'><name><surname>Chen</surname><given-names>Ta-Fu</given-names></name><address><email>tfchen@ntu.edu.tw</email></address><xref rid='Aff1' ref-type='aff'></xref></contrib><contrib contrib-type='author'><name><surname>Cheng</surname><given-names>Ting-Wen</given-names></name><address><email>r91227024@ntu.edu.tw</email></address><xref rid='Aff1' ref-type='aff'></xref></contrib><contrib contrib-type='author'><name><surname>Lai</surname><given-names>Ya-Mei</given-names></name><address><email>yameilai@ntuh.gov.tw</email></address><xref rid='Aff1' ref-type='aff'></xref></contrib><contrib contrib-type='author'><name><surname>Hua</surname><given-names>Mau-Sun</given-names></name><address><email>huams@ntu.edu.tw</email></address><xref rid='Aff2' ref-type='aff'></xref></contrib><contrib contrib-type='author' corresp='yes'><name><surname>Chen</surname><given-names>Ya-Fang</given-names></name><address><phone>+886 2-2312-3456</phone><email>joannayfc@gmail.com</email></address><xref rid='Aff3' ref-type='aff'></xref></contrib><contrib contrib-type='author' corresp='yes'><name><surname>Chiu</surname><given-names>Ming-Jang</given-names></name><address><phone>+886-2-2312-3456</phone><email>mjchiu@ntu.edu.tw</email></address><xref rid='Aff1' ref-type='aff'></xref><xref rid='Aff2' ref-type='aff'></xref></contrib><aff id='Aff1'><label></label>Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan S Rd., Taipei, 100 Taiwan </aff><aff id='Aff2'><label></label>Department of Psychology, College of Science, National Taiwan University, Taipei, Taiwan </aff><aff id='Aff3'><label></label>Department of Medical Imaging, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan S. Rd., Taipei, 100 Taiwan </aff></contrib-group><pub-date pub-type='epub'><day>23</day><month>11</month><year>2015</year></pub-date><pub-date pub-type='pmc-release'><day>23</day><month>11</month><year>2015</year></pub-date><pub-date pub-type='collection'><year>2015</year></pub-date><volume>7</volume><elocation-id>72</elocation-id><history><date date-type='received'><day>2</day><month>8</month><year>2015</year></date><date date-type='accepted'><day>13</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>© Cheng et al. 2015</copyright-statement><license license-type='OpenAccess'><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by/4.0/'>http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/publicdomain/zero/1.0/'>http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id='Abs1'><sec><title>Introduction</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>This study aimed to investigate the feasibility of predicting the long–term effects of cholinesterase inhibitors (ChEI) with common clinical neuroimaging parameters of Alzheimer’s disease, including medial temporal lobe atrophy (MTA) and white matter hyperintensity (WMH).</s></p></sec><sec><title>Method</title><p><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1><CoreSc2 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc2>A cohort of 353 patients with very mild to moderate Alzheimer’s disease received cholinesterase inhibitors and were followed for a median of 46.6 months.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Baseline clinical data, including age, educational level, Clinical Dementia Rating (CDR), Taiwanese Mental State Examination (TMSE), and visual scoring for MTA and WMH were tested as possible predictive factors that influence the survival from a TMSE decline of at least 3 points.</s></p></sec><sec><title>Results</title><p><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>During the follow-up period, 162(46 %) patients had a significant TMSE decline.</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Patients with age-adjusted prominent MTA had a significantly shorter TMSE-decline free interval than those without (43.4 ± 4.5 months vs. 68.2 ± 9.5 months, log rank test p-value =0.001).</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> However, the severity of WMH does not significantly influence cognitive outcomes.</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Cox regression analysis identified that younger age at the time of starting ChEI (p &lt; 0.0005) and higher total MTA scores (p = 0.002) predict a more rapid TMSE decline under ChEI therapy.</s></p></sec><sec><title>Conclusions</title><p><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Younger age at the time of starting ChEI and higher visual scoring of MTA may imply a more advanced Alzheimer’s pathology.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> WMH load is not a prognostic indicator of treatment response to ChEI.</s></p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type='introduction' id='Sec1'><title>Introduction</title><p><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Cholinesterase inhibitors (ChEIs) are the only currently available medications that may modestly decrease the cognitive impairment in patients with mild to moderate Alzheimer’s disease (AD) [<xref rid='CR1' ref-type='bibr'>1</xref>–<xref rid='CR3' ref-type='bibr'>3</xref>].</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, the variable response between patients, relatively high long-term costs, and adverse effects make the general application of ChEIs for all patients with early AD unavailable.</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Several studies have tried to identify clinical and neuroimaging characteristics that might predict the cognitive response to ChEI therapy [<xref rid='CR4' ref-type='bibr'>4</xref>–<xref rid='CR8' ref-type='bibr'>8</xref>].</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, these studies were often limited by their small sample size and short period of follow up.</s></p><p><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The medial temporal lobe is known to be the initial site of pathological changes of AD [<xref rid='CR9' ref-type='bibr'>9</xref>].</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Previous studies have shown that the degree of medial temporal atrophy (MTA) was associated with the risk of progression from mild cognitive impairment (MCI) to AD [<xref rid='CR10' ref-type='bibr'>10</xref>–<xref rid='CR12' ref-type='bibr'>12</xref>], the disease stage [<xref rid='CR13' ref-type='bibr'>13</xref>], and the rate of cognitive decline [<xref rid='CR14' ref-type='bibr'>14</xref>].</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Meanwhile, the association between MTA and the long-term therapeutic response to ChEI is not well established.</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Another neuroimaging characteristic is the white matter hyperintensity (WMH), which is viewed by some researchers as an indicator of the underlying vascular burden that contributes to cognitive dysfunction [<xref rid='CR15' ref-type='bibr'>15</xref>, <xref rid='CR16' ref-type='bibr'>16</xref>].</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In Taiwan, most of our AD patients who receive ChEI are reimbursed by the National Health Insurance System.</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A more extensive WMH was one of the exclusion criteria that precluded patients from ChEI paid for by the national insurance; there was a concern that this might indicate an underlying vascular pathology, in addition to Alzheimer’s pathology [<xref rid='CR17' ref-type='bibr'>17</xref>].</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Recent studies have shown an increased burden of WMH with an increasing severity of AD [<xref rid='CR18' ref-type='bibr'>18</xref>, <xref rid='CR19' ref-type='bibr'>19</xref>].</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> However, whether or not the presence of WMH would influence the cognitive response to ChEI therapy remains undetermined.</s></p><p><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>We aimed to identify common neuroimaging indicators for the cognitive outcome predictors in AD patients who received ChEI therapy.</s></p></sec><sec id='Sec2'><title>Method</title><sec id='Sec3'><title>Patient recruitment</title><p><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>We recruited patients with very mild to moderate AD, Clinical Dementia Rating (CDR) scored 0.5 ~ 2, who received both cholinesterase inhibitor therapy and regular follow-up at the memory clinic of National Taiwan University Hospital, from August 1999 to June 2012.</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The diagnosis of AD was made after a comprehensive history review, neurological examination, laboratory survey, and neuroimaging study.</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> All of the patients met the diagnostic criteria for probable AD dementia proposed by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-NDRDA) work group in 1984 [<xref rid='CR20' ref-type='bibr'>20</xref>].</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Before starting the cholinesterase inhibitor, clinical data were collected prospectively, including basic demographic data, education level, baseline TMSE (Taiwanese Mini-Mental State Examination) score [<xref rid='CR21' ref-type='bibr'>21</xref>, <xref rid='CR22' ref-type='bibr'>22</xref>], and CDR.</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> A standardized regular follow up of TMSE and CDR was carried out before the trial, six months after, and annually after starting the cholinesterase inhibitor.</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Patients who were lost to follow-up within six months of cholinesterase use (seven patients, 2 % of patients initially recruited) were excluded, given that there were no clinical data available for evaluation of their response to ChEI.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The ChEIs used in this cohort included donepezil (n = 240, 68 %), rivastigmine (n = 59, 17 %), and galantamine (n = 54, 15 %).</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The dosages of ChEIs were titrated up to the standard daily dose of 5 to 10 mg for donepezil, 6–9 mg for rivastigmine, and 16 mg for galantamine (if tolerable); changing from one ChEI to another was allowed if intolerable side effects were encountered.</s></p></sec><sec id='Sec4'><title>Image acquisition</title><p><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Brain computed tomography was performed using one of our multi-detector CT scanners, including GE LightSpeed 16, VCT (GE Healthcare, Milwaukee, WI, USA), SOMATOM Sensation 64, and Emotion 16 (Siemens Medical Solutions, Erlangen, Germany).</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Axial cuts were taken at the top of the C1 lamina through the top of the calvarium.</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Axial images were reconstructed with 5-mm-thick sections at 5-mm intervals.</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> In some of our subjects, coronal reconstructed images of 5 mm thickness were also available.</s></p><p><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Magnetic resonance imaging (MRI) of the brain was performed on a 1.5TMR unit, either GE Excite (GE Healthcare) or MAGNETOM Sonata (Siemens Healthcare).</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The scanning protocol included axial FLAIR, fast spin-echo T2-weighted sequences, and a coronal T1WI or a 3D T1WI.</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The axial slices were positioned to run parallel to a line that joins the most inferoanterior and inferoposterior parts of the corpus callosum and had a thickness of 5 mm with a gap of 1.5 mm.</s></p></sec><sec id='Sec5'><title>Visual scoring for medial temporal atrophy and white matter hyperintensity</title><p><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>MTA was rated on a coronal view of brain CT or T1-weighted MRI, using the scoring system proposed by Scheltens <italic>et al.</italic> [<xref rid='CR23' ref-type='bibr'>23</xref>].</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Each side of the medial temporal lobe and hippocampus was scored from 0 to 4.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> A higher MTA score indicated a higher degree of medial temporal lobe atrophy.</s></p><p><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>As the correlation of aging and MTA has been well established, we defined prominent MTA according to the patient’s age upon recruitment.</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> A prominent MTA was defined as a MTA score more than 1 on either side for patients 75-years-old and under.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> For patients older than 75 years, a MTA score more than 2 was required to define a prominent MTA.</s></p><p><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>To determine the extent of WMH, a visual scoring system modified from that suggested by Fazekas <italic>et al.</italic> [<xref rid='CR24' ref-type='bibr'>24</xref>] was used.</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Each brain CT or MRI scan of the FLAIR series was rated from 0 to 3 on a coronal view, across two brain areas: frontal and parietal lobes of either side.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The total WMH was scored 0 ~ 12, with the higher score indicating more extensive white matter hyperintensity.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> For WMH scoring, there is generally no accepted cut-off-point for different age groups.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We defined a significant WMH if a brain area had a WMH score of 2 or above.</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The participants were stratified according to the severity of WMH, which included: (1) the presence of a significant WMH in any of the four brain areas; (2) the number of brain areas with significant WMH; and (3) the summation of the WMH scores in all four brain areas.</s></p><p><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>To determine the inter-rater reliability of visual scoring, 20 MRI or CT scans were rated for MTA and WMH scoring by two independent raters (YFC and YWC) who were blinded to the clinical data.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The inter-rater reliability study showed good agreement between raters for both visual scoring for MTA (intra-class correlation coefficient = 0.954) and WMH (intra-class correlation coefficient = 0.950).</s></p><p><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The study was approved by the National Taiwan University Hospital’s Institutional Review Board.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> All investigations were conducted according to the principles expressed in the Declaration of Helsinki.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> We obtained written informed consent from the participants or their proxies.</s></p></sec><sec id='Sec6'><title>Statistical analysis</title><p><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>We used the Pearson chi-square test to compare the between-group differences of categorical variables and the Mann Whitney <italic>U</italic> test for numerical variables.</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The Log rank test was used for survival data.</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Stepwise linear regression analysis was performed separately to evaluate factors associated with a significant MTA and WMH.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Inter-rater reliability for the visual ratings of WMH and MTA were measured by intra-class correlation coefficients.</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> To access the cognitive response to cholinesterase inhibitors, we performed a survival analysis; we plotted the Kaplan-Meier survival curve by setting the endpoint as a significant TMSE decline from the baseline of more than 2 points.</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Patients who passed away or were lost to follow-up before a clinical evaluation at six months were excluded.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> A Cox proportional hazard model was applied to analyze factors affecting the time until a significant TMSE decline.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Data were analyzed using the statistical software PASW for windows, version 18.0.</s></p></sec></sec><sec sec-type='results' id='Sec7'><title>Results</title><p><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Three hundred and fifty-three patients (217 women and 136 men) with very mild to moderate AD were included in this study.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The median duration of follow up was 46.6 (7.47 ~ 157.4) months.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The mean age of the population was 74.1 ± 10.3 years with a mean education level of 8.9 ± 5.1 years; their mean baseline TMSE score was 19.7 ± 4.1 points and mean CDR score was 0.5 in 195 (55 %) patients, 1 in 129 (36 %) patients, and 2 in 19(5 %) patients (Table <xref rid='Tab1' ref-type='table'>1</xref>).</s><table-wrap id='Tab1'><label>Table 1</label><caption><p>Demographic data and neuroimaging characteristics of the subjects</p></caption><table rules='groups' frame='hsides'><thead><tr><th>Baseline characteristics</th><th>Mean ± SD, or number (%)</th></tr></thead><tbody><tr><td>Age of starting ChEI (year)</td><td>74.1 ± 10.3</td></tr><tr><td>Gender, female/male, No. (%)</td><td>218/135 (62/38)</td></tr><tr><td>Education (year)</td><td>8.9 ± 5.1</td></tr><tr><td>Baseline TMSE</td><td>19.7 ± 4.1</td></tr><tr><td>Baseline CDR, No. (%)</td><td></td></tr><tr><td> 0.5</td><td>195 (55)</td></tr><tr><td> 1</td><td>129 (36)</td></tr><tr><td> 2 ~ 3</td><td>19 (5)</td></tr><tr><td>Total MTA score</td><td>3.4 ± 1.7</td></tr><tr><td>Maximum MTA score, No. (%)</td><td></td></tr><tr><td> 0</td><td>23 (7)</td></tr><tr><td> 1</td><td>86 (24)</td></tr><tr><td> 2</td><td>174 (49)</td></tr><tr><td> 3</td><td>61 (17)</td></tr><tr><td> 4</td><td>9 (3)</td></tr><tr><td>Prominent MTA adjusted by age, No. (%)</td><td>136 (39)</td></tr><tr><td>Total WMH score</td><td>3.6 ± 3.1</td></tr><tr><td>Total WMH score, No. (%)</td><td></td></tr><tr><td> 0 ~ 3</td><td>165 (47)</td></tr><tr><td> 4 ~ 7</td><td>125 (35)</td></tr><tr><td> 8 ~ 12</td><td>64 (18)</td></tr><tr><td>Number of areas with WMH score &gt; =2</td><td></td></tr><tr><td> 0</td><td>237 (67)</td></tr><tr><td> 1 ~ 2</td><td>49 (14)</td></tr><tr><td> 3 ~ 4</td><td>67 (19)</td></tr></tbody></table><table-wrap-foot><p><italic>CDR</italic> Clinical Dementia Rating, <italic>ChEI</italic> cholinesterase inhibitor, <italic>MTA</italic> medial temporal atrophy, <italic>TMSE</italic> Taiwanese Mini-Mental State Examination, <italic>WMH</italic> white matter hyperintensity</p></table-wrap-foot></table-wrap></p><p><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Patients were followed until the study end-point, death, or loss to follow-up.</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In summary, 162 (45.8 %) patients reached an end point (a more than two-point TMSE decline), 10 (2.8 %) died, and 65 (8.4 %) were lost to follow-up before a significant TMSE decline.</s></p><p><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The mean survival time from a significant TMSE decline of all patients was 56.0 ± 5.2 months.</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The Kaplan-Meier survival curve for the TMSE decline did not differ significantly between patients with or without a significant WMH (a dichotomy), defined as a WMH score of two or more points at any brain area (log rank test p-value = 0.540).</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> There were no significant differences in the survival curves between patients stratified by a total WMH dichotomy of 0–3 versus 4–12 (log rank test p-value = 0.431); there was no significant difference among the three groups, comprising a score of 0 to 3, 4 to 7, and 8 to 12 (log rank test p-value = 0.514); in addition, there was no significant difference among patient groups stratified by number of areas (a trichotomy) with significant WMH of 0, 1 ~ 2, or 3 ~ 4 areas (log rank test p-value = 0.142).</s></p><p><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>On the other hand, patients with a prominent MTA had a shorter TMSE decline-free survival under treatment with a ChEI (Fig. <xref rid='Fig1' ref-type='fig'>1a</xref>, log rank test p-value = 0.001).</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The median survival time from significant TMSE decline was 68.2 ± 9.5 months for patients without prominent MTA (n = 217, 61 % censored), compared with 43.4 ± 4.5 months for patients with prominent MTA (n = 136, 43 % censored).</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> When we exclude those patients who were lost to follow up during the study period, the remaining 278 patients still showed a significantly shorter TMSE decline-free survival for patients with prominent MTA (log rank test p-value &lt; 0.0005).<fig id='Fig1'><label>Fig. 1</label><caption><p>TMSE decline-free survival under ChEI therapy. The Kaplan-Meier survival curves were plotted by setting the endpoint as a significant TMSE decline from the baseline for more than 2 points, for <bold>a</bold> all patients (N = 353, log rank test p-value = 0.001), <bold>b</bold> patients 60-years old or older (N = 308, log rank test p-value = 0.019), and <bold>c</bold> patients younger than 60-years old (N = 45, log rank test p-value = 0.071). Prominent MTA predicted shorter TMSE-decline free survival for patients 60-years old or older when starting ChEI therapy. <italic>TMSE</italic> Taiwanese Mini-Mental State Examination, <italic>ChEI</italic> cholinesterase inhibitor</p></caption><graphic id='MO1' xlink:href='13195_2015_155_Fig1_HTML'></graphic></fig></s></p><p><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>To illustrate the effect of individual demographics and neuroimaging characteristics as risk factors on TMSE decline-free survival, we performed forward stepwise Cox regression analysis for independent variables; the variables included age of starting ChEI, gender, educational level (by year), baseline TMSE, CDR, total MTA score, and total WMH score.</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Younger age at the time of starting ChEI (p &lt; 0.0005) and higher total MTA score (p = 0.002) predicted a more rapid decline of TMSE while receiving ChEI therapy (Table <xref rid='Tab2' ref-type='table'>2</xref>).</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The total WMH score did not significantly predict the TMSE decline-free survival.</s><table-wrap id='Tab2'><label>Table 2</label><caption><p>Regression coefficients in Cox proportional hazard models of factors associated with TMSE decline-free survival</p></caption><table rules='groups' frame='hsides'><thead><tr><th colspan='2'>Model</th><th>B</th><th>SE</th><th>Exp(B) (95 % CI)</th><th>P-value</th></tr></thead><tbody><tr><td>Model I</td><td>Age of starting ChEI</td><td char='.' align='char'>−0.030</td><td char='.' align='char'>0.008</td><td>0.971 (0.955 ~ 0.986)</td><td>&lt;0.0005</td></tr><tr><td rowspan='2'>Model II</td><td>Age of starting ChEI</td><td char='.' align='char'>−0.035</td><td char='.' align='char'>0.008</td><td>0.965 (0.949 ~ 0.981)</td><td>&lt;0.0005</td></tr><tr><td>Total MTA score</td><td char='.' align='char'>0.147</td><td char='.' align='char'>0.047</td><td>1.158 (1.056 ~ 1.271)</td><td>0.002</td></tr></tbody></table><table-wrap-foot><p><italic>CDR</italic> Clinical Dementia Rating, <italic>ChEI</italic> cholinesterase inhibitor, <italic>MTA</italic> medial temporal atrophy, <italic>TMSE</italic> Taiwanese Mini-Mental State Examination, <italic>WMH</italic> white matter hyperintensity, <italic>CI</italic> confidence interval; excluded variables in Model II: gender, educational level, baseline TMSE, baseline CDR, and total WMH score; excluded variables in Model I: gender, educational level, baseline TMSE, baseline CDR, total WMH score, and total MTA score</p></table-wrap-foot></table-wrap></p><p><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Because age was a significant confounding factor that strongly predicted TMSE decline-free survival, we compared the Kaplan-Meier survival curves between different age groups.</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> We found that the survival curves differ significantly for patients 60-years old or less from those older than 60 years (Fig. <xref rid='Fig2' ref-type='fig'>2</xref>, log rank test p-value &lt; 0.0005).</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We performed subgroup analysis, according to age, in order to compare the significance of WMH and MTA in separating the Kaplan-Meier survival curve.</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The severity of WMH did not separate the survival curve significantly in patients either younger or older than 60-years old.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> On the other hand, a prominent MTA consistently predicted shorter TMSE-decline free survival (Fig. <xref rid='Fig1' ref-type='fig'>1b</xref>, log rank test p-value = 0.019) for patients 60-years old or older (n = 308).</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The median survival time was 70.4 ± 7.9 months for patients without prominent MTA (n = 195, 63 % censored), compared with 47.4 ± 6.2 months for patients with prominent MTA (n = 113, 49 % censored).</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> For younger patients (n = 45), a similar trend was present (Fig. <xref rid='Fig1' ref-type='fig'>1c</xref>, log rank test p-value = 0.071).</s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In patients 60-years old or younger, the median survival time was 35.7 ± 4.2 months in patients without MTA, compared with 25.3 ± 3.5 months for those with significant MTA.<fig id='Fig2'><label>Fig. 2</label><caption><p>TMSE decline-free survival between patients stratified by different age groups. Patients who started ChEI therapy at the age of 60 years or younger had a more rapid TMSE decline as compared to other age groups <italic>TMSE</italic> Taiwanese Mini-Mental State Examination, <italic>ChEI</italic> cholinesterase inhibitor</p></caption><graphic id='MO2' xlink:href='13195_2015_155_Fig2_HTML'></graphic></fig></s></p><p><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>We performed a multiple stepwise linear regression analysis by using the total MTA score or total WMH score as dependent variables to separately identify their respective predictive factors.</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The examined independent variables included the patient’s age, educational level, baseline CDR, baseline TMSE, and total WMH score or total MTA score.</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> We found that a higher total WMH score, higher educational level, and lower TMSE are associated with a higher total MTA score (Table <xref rid='Tab3' ref-type='table'>3</xref>).</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> On the other hand, an older age (p &lt; 0.0005), a higher total MTA score (p &lt; 0.0005), and a higher baseline CDR score (p = 0.003) are associated with a higher total WMH score (adjusted R<sup>2</sup> 0.276).</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We also examined the effect of vascular risk factors on the total WMH and MTA scores.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We used age, education level, hypertension (n = 265), diabetes mellitus (n = 266), hyperlipidemia (n = 260), and obstructive sleep apnea (n = 228, represented by snoring) as independent variables in multiple stepwise linear regression analyses.</s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In addition to older age (p &lt; 0.0005), we found only the presence of diabetes mellitus (p = 0.007) was positively associated with the total WMH score (adjusted R<sup>2</sup> 0.186).</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> However, no vascular risk factor was associated with the total MTA score.</s><table-wrap id='Tab3'><label>Table 3</label><caption><p>Regression coefficients in linear regression models of factors associated with total MTA score</p></caption><table rules='groups' frame='hsides'><thead><tr><th colspan='2'>Model</th><th>B (95 % CI)</th><th>β</th><th>P-value</th><th>Adjusted R<sup>2</sup></th></tr></thead><tbody><tr><td>I</td><td>Total WMH score</td><td>0.202 (0.147 ~ 0.258)</td><td char='.' align='char'>0.361</td><td>&lt;0.0005</td><td>0.128</td></tr><tr><td rowspan='2'>II</td><td>Total WMH score</td><td>0.181 (0.124 ~ 0.237)</td><td char='.' align='char'>0.323</td><td>&lt;0.0005</td><td rowspan='2'>0.150</td></tr><tr><td>Baseline CDR</td><td>0.728 (0.275 ~ 1.182)</td><td char='.' align='char'>0.162</td><td>0.002</td></tr><tr><td rowspan='3'>III</td><td>Total WMH score</td><td>0.186 (0.130 ~ 0.242)</td><td char='.' align='char'>0.332</td><td>&lt;0.0005</td><td rowspan='3'>0.173</td></tr><tr><td>Baseline CDR</td><td>0.822 (0.371 ~ 1.273)</td><td char='.' align='char'>0.183</td><td>&lt;0.0005</td></tr><tr><td>Education (year)</td><td>0.053 (0.020 ~ 0.086)</td><td char='.' align='char'>0.160</td><td>0.001</td></tr><tr><td rowspan='4'>IV</td><td>Total WMH score</td><td>0.187 (0.133 ~ 0.242)</td><td char='.' align='char'>0.334</td><td>&lt;0.0005</td><td rowspan='4'>0.207</td></tr><tr><td>Baseline CDR</td><td>0.406 (−0.028 ~ 0.894)</td><td char='.' align='char'>0.090</td><td>0.102</td></tr><tr><td>Education (year)</td><td>0.086 (0.051 ~ 0.122)</td><td char='.' align='char'>0.260</td><td>&lt;0.0005</td></tr><tr><td>Baseline TMSE</td><td>−0.099 (−0.149 ~ −0.050)</td><td char='.' align='char'>−0.240</td><td>&lt;0.0005</td></tr><tr><td rowspan='3'>V</td><td>Total WMH score</td><td>0.197 (0.143 ~ 0.250)</td><td char='.' align='char'>0.351</td><td>&lt;0.0005</td><td rowspan='3'>0.203</td></tr><tr><td>Education (year)</td><td>0.089 (0.053 ~ 0.125)</td><td char='.' align='char'>0.268</td><td>&lt;0.0005</td></tr><tr><td>Baseline TMSE</td><td>−0.117 (−0.162 ~ −0.072)</td><td char='.' align='char'>−0.282</td><td>&lt;0.0005</td></tr></tbody></table><table-wrap-foot><p><italic>CDR</italic> Clinical Dementia Rating, <italic>ChEI</italic> cholinesterase inhibitor, <italic>MTA</italic> medial temporal atrophy, <italic>TMSE</italic> Taiwanese Mini-Mental State Examination, <italic>WMH</italic> white matter hyperintensity, <italic>CI</italic> confidence interval; Variables entered into stepwise linear regression analysis: age of starting ChEI, educational level, baseline TMSE, baseline CDR, and total WMH score</p></table-wrap-foot></table-wrap></p></sec><sec sec-type='discussion' id='Sec8'><title>Discussion</title><p><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>In this study, we founded that: (1) for patients with mild to moderate AD, a lower total MTA score and an older age predicted a better long term cognitive response to ChEI therapy, defined by a longer TMSE decline-free survival; (2) the severity of WMH does not significantly affect the TMSE decline-free survival; (3) a higher total MTA score was associated with a higher WMH score, higher educational level, and a lower baseline TMSE; and (4) a higher total WMH score was associated with older age, higher total MTA score, and higher baseline CDR.</s></p><p><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>There are two unique features of this study: first, simple visual scoring for MTA and WMH were used as neuroimaging markers, which are easily applicable in daily clinical practice; second, we used long term TMSE decline-free survival as the endpoint for response to ChEI treatment, rather than short term cognitive improvement, which has been used in most of the previous studies.</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We set our outcome measurement as the time until a TMSE decline of three or more points and our median follow up time was 46.6 months.</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Compared with the short -term cognitive response within months, the long-term outcome may be of higher clinical importance for both the patients and the insurance carriers.</s></p><p><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In previous studies, volumetric measurements for medial temporal lobe atrophy, hippocampal atrophy, and entorhinal cortex thinning were associated with a poorer cognitive response after ChEI therapy for four or six months [<xref rid='CR5' ref-type='bibr'>5</xref>, <xref rid='CR6' ref-type='bibr'>6</xref>].</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Findings of our study imply that this effect may last for several years (median observation period of approximately four years).</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Although the volumetric measurement is quantitative and draws less concern regarding inter-rater reliability, the technique is technically demanding and time consuming.</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This makes this technique not conveniently applicable in routine clinical practice.</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It was shown by Duara <italic>et al.</italic> that a higher cut-point for MTA score is required for older subjects in order to separate AD patients from age-matched controls [<xref rid='CR25' ref-type='bibr'>25</xref>].</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In the original study of Scheltens <italic>et al.</italic> [<xref rid='CR24' ref-type='bibr'>24</xref>], a visual scoring of two or more successfully separated AD patients from age-matched controls; the median age of the study participants was 72.8 years.</s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In another study by Duara <italic>et al.</italic> [<xref rid='CR26' ref-type='bibr'>26</xref>], the authors reported a mean MTA score of 2.45 on the left side and 2.43 on the right side in a group of 53 AD patients who had a mean age of 79.9 years.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In this study, we define a “prominent MTA” as a MTA score of three or more for patients older than 75 years and a MTA score of two or more for patients 75 years old or younger.</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> This age-adjusted cut-off-score for defining “prominent MTA” subsequently performed better in separating the TMSE decline-free survival curve under ChEI treatment.</s><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This finding is concordant with previous studies using volumetric measurements; this validates the visual scoring for MTA measurement as a marker for the rate of TMSE decline.</s></p><p><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Unlike MTA, the role of white matter change in disease progression and response to ChEI therapy for AD patients remains controversial [<xref rid='CR27' ref-type='bibr'>27</xref>].</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In a study by Connelly <italic>et al.</italic>, the presence of both hypertension and white matter lesions was associated with a less favorable functional outcome after ChEI therapy for six months [<xref rid='CR7' ref-type='bibr'>7</xref>].</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Other studies failed to show a significant correlation between the severity of WMH and cognitive or functional outcome after ChEI therapy for three months [<xref rid='CR4' ref-type='bibr'>4</xref>], one year [<xref rid='CR28' ref-type='bibr'>28</xref>], or nine months or more [<xref rid='CR8' ref-type='bibr'>8</xref>].</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> On the other hand, when considering the subcortical hyperintensities in the cholinergic pathways using the Cholinergic Pathways Hyperintensities Scale (CHIPS), Behl <italic>et al.</italic> showed that patients in the high CHIPS group had improvement in executive functioning and working memory tasks after receiving ChEI therapy for one year [<xref rid='CR28' ref-type='bibr'>28</xref>].</s><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Our study enrolled a large sample size and had a relatively long follow-up period; we observed no significant correlation between the severity of WMH and ChEI therapeutic responses, in terms of the TMSE decline-free survival.</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Regarding the global white matter lesion burden, the WMH scoring cannot differentiate an underlying pathological change or anatomical involvement.</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> For patients with AD, the white matter changes may be part of the subcortical changes secondary to the underlying neurodegenerative process [<xref rid='CR29' ref-type='bibr'>29</xref>]; alternatively, it may be related to concurrent vascular disease or vascular risk factors [<xref rid='CR30' ref-type='bibr'>30</xref>–<xref rid='CR32' ref-type='bibr'>32</xref>].</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> In order to exclude the possible confounding effect of vascular risk factors on the total WMH and MTA scores, we used hypertension, hyperlipidemia, diabetes mellitus [<xref rid='CR31' ref-type='bibr'>31</xref>], and obstructive sleep apnea [<xref rid='CR32' ref-type='bibr'>32</xref>] as independent variables in multiple stepwise linear regression analyses and found that in addition to old age, diabetes mellitus is the only risk factor that was related to total WMH scores.</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> The heterogeneous pathophysiology underlying global white matter change may be an important reason why the WMH rating was less effective in predicting outcomes.</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Rating the subcortical involvement of the cholinergic pathway may have more of a clinical implication, although it may be less applicable in daily clinical practice [<xref rid='CR8' ref-type='bibr'>8</xref>, <xref rid='CR28' ref-type='bibr'>28</xref>].</s></p><p><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>Linear regressions showed that the severity of MTA was positively associated with the severity of WMH and educational level; it was negatively associated with baseline TMSE.</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The association of WMH with MTA was independent of age, TMSE, or CDR.</s><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> This supports the possible common neurodegenerative process that underlies both MTA and WMH.</s><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Another interesting finding was the association between the severity of MTA and educational level.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Education has been shown to be a protective factor against the development of MCI and AD in several epidemiological and longitudinal observational studies [<xref rid='CR33' ref-type='bibr'>33</xref>, <xref rid='CR34' ref-type='bibr'>34</xref>].</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The cognitive reserve theory suggests that cognitive activities associated with education, occupational attainment, or leisure may delay the clinical expression of AD pathology by increasing the neuronal reserve or neuronal compensation [<xref rid='CR35' ref-type='bibr'>35</xref>].</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In our study, a higher education level was associated with higher MTA scores.</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> This finding is consistent with the cognitive reserve theory that more advanced neurodegenerative pathology may be present in patients with higher educational levels than those with lower educational level with the same clinical severity.</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A negative association between education and regional cerebral blood flow in the parietotemporal area [<xref rid='CR36' ref-type='bibr'>36</xref>] or gray matter densities in the hippocampal area [<xref rid='CR37' ref-type='bibr'>37</xref>] were also shown in previous studies.</s></p><p><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>There are some limitations to this study.</s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> First, we used the survival time to a significant TMSE decline, instead of the rate of TMSE decline as the outcome measurement.</s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Because the study subjects are from a cohort that received ChEI therapy reimbursed by the National Health Insurance of Taiwan, most of the patients discontinued ChEI therapy once a significant TMSE decline was observed as there was a discontinuation of support from the insurance system.</s><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Nevertheless, the duration before a significant cognitive decline may be more clinically valuable, as this would be more beneficial to prolonging the early stages of AD, considering quality-adjusted life years.</s><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Second, we did not control for the type of ChEI used; this allowed for changing from one ChEI to another when intolerable side effects were encountered.</s><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A previous meta-analysis showed no evidence of any differences in efficacy between different ChEIs [<xref rid='CR1' ref-type='bibr'>1</xref>].</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Clinically, we choose from different ChEIs mainly based on the side effect profile.</s><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Thus, the type of ChEI was not controlled when evaluating the cognitive response.</s><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Finally, visual scoring for measurement of the severity of MTA and WMH was not qualitative and was associated with a ceiling effect [<xref rid='CR38' ref-type='bibr'>38</xref>].</s><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In addition, there was no generally accepted age-specific cut-off for WMH scoring.</s><s sid='137'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The high intra-class correlation coefficient supported good inter-rater agreement in the visual scoring of either WHM or MTA.</s><s sid='138'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> We also found a consistent association between higher MTA scores and poorer cognitive responses; this was found to be independent of age, TMSE, CDR, or education, using the Cox proportional model for survival analysis.</s><s sid='139'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> On the other hand, the severity of WMH did not significantly affect cognitive responses; this was true regardless of the fact that we tried variable stratification strategies, including using the maximal score of the areas, the summation of the total scores from all four areas, or the number of areas with WMH.</s><s sid='140'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These findings suggest that the global assessment of WMH is of little, if any, value in predicting cognitive outcomes while on ChEI therapy.</s></p></sec><sec sec-type='conclusion' id='Sec9'><title>Conclusions</title><p><s sid='141'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Our results support the application of visual scoring of MTA as an indicator in predicting long term cognitive responses to cholinesterase therapy for patients with mild to moderate Alzheimer’s dementia.</s><s sid='142'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> On the other hand, the global assessment of the white matter disease burden may not contribute significantly to cognitive outcomes.</s><s sid='143'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Furthermore, studies including location or pathway specific neuroimaging characteristics are required to identify possible predictive values of different patterns of WMH in the therapeutic response.</s><s sid='144'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> At the current stage, we suggest against the application of the global assessment of the white matter disease burden to exclude patients from clinically efficacious therapy under the diagnosis of Alzheimer’s dementia.</s></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AD</term><def><p>Alzheimer’s disease</p></def></def-item><def-item><term>CDR</term><def><p>Clinical Dementia Rating</p></def></def-item><def-item><term>ChEI</term><def><p>cholinesterase inhibitor</p></def></def-item><def-item><term>MTA</term><def><p>medial temporal atrophy</p></def></def-item><def-item><term>TMSE</term><def><p>Taiwanese Mini-Mental State Examination</p></def></def-item><def-item><term>WMH</term><def><p>white matter hyperintensity</p></def></def-item></def-list></glossary><fn-group><fn><p>Yu-Wen Cheng and Ta-Fu Chen contributed equally to this work.</p></fn><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors’ contributions</bold></p><p>YWC performed the statistical analysis and drafted the manuscript. TFC participated in clinical evaluation, design of the study, and helped draft the manuscript. TWC and YML carried out the neurocognitive evaluation, scoring, and helped to draft the Results part of the manuscript. MSH participated in concept formation in the study design and helped interpret the cognitive evaluation and revised the manuscript. YFC participated in the design and interpretation of the neuroimaging studies and helped draft the manuscript. MJC participated in concept formation, study design, and manuscript drafting, revision and final approval. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the participants in the study. This study was supported by a grant from the Ministry of Science and Technology, Taiwan (TW) (103-2314-B002-175).</p></ack><ref-list id='Bib1'><title>References</title><ref id='CR1'><label>1.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Birks</surname><given-names>J</given-names></name></person-group><article-title>Cholinesterase inhibitors for Alzheimer’s disease</article-title><source>Cochrane Database Syst Rev</source><year>2006</year><volume>25</volume><fpage>Cd005593</fpage><pub-id pub-id-type='pmid'>16437532</pub-id></element-citation></ref><ref id='CR2'><label>2.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Mangialasche</surname><given-names>F</given-names></name><name><surname>Solomon</surname><given-names>A</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Mecocci</surname><given-names>P</given-names></name><name><surname>Kivipelto</surname><given-names>M</given-names></name></person-group><article-title>Alzheimer’s disease: clinical trials and drug development</article-title><source>Lancet Neurol</source><year>2010</year><volume>9</volume><fpage>702</fpage><lpage>16</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(10)70119-8</pub-id><pub-id pub-id-type='pmid'>20610346</pub-id></element-citation></ref><ref id='CR3'><label>3.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Mangialasche</surname><given-names>F</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Giacobini</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014</article-title><source>J Intern Med</source><year>2014</year><volume>275</volume><fpage>251</fpage><lpage>83</lpage><pub-id pub-id-type='doi'>10.1111/joim.12191</pub-id><pub-id pub-id-type='pmid'>24605808</pub-id></element-citation></ref><ref id='CR4'><label>4.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Amar</surname><given-names>K</given-names></name><name><surname>Wilcock</surname><given-names>GK</given-names></name><name><surname>Scot</surname><given-names>M</given-names></name><name><surname>Lewis</surname><given-names>T</given-names></name></person-group><article-title>The presence of leuko-araiosis in patients with Alzheimer’s disease predicts poor tolerance to tacrine, but does not discriminate responders from non-responders</article-title><source>Age Ageing</source><year>1997</year><volume>26</volume><fpage>25</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1093/ageing/26.1.25</pub-id><pub-id pub-id-type='pmid'>9143434</pub-id></element-citation></ref><ref id='CR5'><label>5.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Hanyu</surname><given-names>H</given-names></name><name><surname>Sakurai</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Takasaki</surname><given-names>M</given-names></name></person-group><article-title>Characteristics of MRI features in Alzheimer’s disease patients predicting response to donepezil treatment</article-title><source>Nippon Ronen Igakkai Zasshi</source><year>2003</year><volume>40</volume><fpage>261</fpage><lpage>6</lpage><pub-id pub-id-type='doi'>10.3143/geriatrics.40.261</pub-id><pub-id pub-id-type='pmid'>12822478</pub-id></element-citation></ref><ref id='CR6'><label>6.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Connelly</surname><given-names>PJ</given-names></name><name><surname>Prentice</surname><given-names>NP</given-names></name><name><surname>Fowler</surname><given-names>KG</given-names></name></person-group><article-title>Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer’s disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2005</year><volume>76</volume><fpage>320</fpage><lpage>4</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.2004.043539</pub-id><pub-id pub-id-type='pmid'>15716519</pub-id></element-citation></ref><ref id='CR7'><label>7.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Connelly</surname><given-names>PJ</given-names></name><name><surname>Prentice</surname><given-names>NP</given-names></name><name><surname>Fowler</surname><given-names>KG</given-names></name></person-group><article-title>Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer’s disease</article-title><source>Int J Geriatr Psychiatry</source><year>2005</year><volume>20</volume><fpage>623</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1002/gps.1331</pub-id><pub-id pub-id-type='pmid'>16021654</pub-id></element-citation></ref><ref id='CR8'><label>8.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Devine</surname><given-names>ME</given-names></name><name><surname>Fonseca</surname><given-names>JA</given-names></name><name><surname>Walker</surname><given-names>RW</given-names></name><name><surname>Sikdar</surname><given-names>T</given-names></name><name><surname>Stevens</surname><given-names>T</given-names></name><name><surname>Walker</surname><given-names>Z</given-names></name></person-group><article-title>Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study</article-title><source>Int J Geriatr Psychiatry</source><year>2007</year><volume>22</volume><fpage>1120</fpage><lpage>6</lpage><pub-id pub-id-type='doi'>10.1002/gps.1799</pub-id><pub-id pub-id-type='pmid'>17457951</pub-id></element-citation></ref><ref id='CR9'><label>9.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><year>1991</year><volume>82</volume><fpage>239</fpage><lpage>59</lpage><pub-id pub-id-type='doi'>10.1007/BF00308809</pub-id><pub-id pub-id-type='pmid'>1759558</pub-id></element-citation></ref><ref id='CR10'><label>10.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Xu</surname><given-names>YC</given-names></name><name><surname>O’Brien</surname><given-names>PC</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Ivnik</surname><given-names>RJ</given-names></name><etal></etal></person-group><article-title>Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment</article-title><source>Neurology</source><year>1999</year><volume>52</volume><fpage>1397</fpage><lpage>403</lpage><pub-id pub-id-type='doi'>10.1212/WNL.52.7.1397</pub-id><pub-id pub-id-type='pmid'>10227624</pub-id></element-citation></ref><ref id='CR11'><label>11.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Korf</surname><given-names>ES</given-names></name><name><surname>Wahlund</surname><given-names>LO</given-names></name><name><surname>Visser</surname><given-names>PJ</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name></person-group><article-title>Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment</article-title><source>Neurology</source><year>2004</year><volume>63</volume><fpage>94</fpage><lpage>100</lpage><pub-id pub-id-type='doi'>10.1212/01.WNL.0000133114.92694.93</pub-id><pub-id pub-id-type='pmid'>15249617</pub-id></element-citation></ref><ref id='CR12'><label>12.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Devanand</surname><given-names>DP</given-names></name><name><surname>Pradhaban</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Khandji</surname><given-names>A</given-names></name><name><surname>De Santi</surname><given-names>S</given-names></name><name><surname>Segal</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>828</fpage><lpage>36</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000256697.20968.d7</pub-id><pub-id pub-id-type='pmid'>17353470</pub-id></element-citation></ref><ref id='CR13'><label>13.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>O’Brien</surname><given-names>PC</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Ivnik</surname><given-names>RJ</given-names></name><etal></etal></person-group><article-title>Rates of hippocampal atrophy correlate with change in clinical status in aging and AD</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>484</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1212/WNL.55.4.484</pub-id><pub-id pub-id-type='pmid'>10953178</pub-id></element-citation></ref><ref id='CR14'><label>14.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Velayudhan</surname><given-names>L</given-names></name><name><surname>Proitsi</surname><given-names>P</given-names></name><name><surname>Westman</surname><given-names>E</given-names></name><name><surname>Muehlboeck</surname><given-names>JS</given-names></name><name><surname>Mecocci</surname><given-names>P</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Entorhinal cortex thickness predicts cognitive decline in Alzheimer’s disease</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>33</volume><fpage>755</fpage><lpage>66</lpage><pub-id pub-id-type='pmid'>23047370</pub-id></element-citation></ref><ref id='CR15'><label>15.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Black</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Bilbao</surname><given-names>J</given-names></name></person-group><article-title>Understanding white matter disease: imaging-pathological correlations in vascular cognitive impairment</article-title><source>Stroke</source><year>2009</year><volume>40</volume><fpage>S48</fpage><lpage>52</lpage><pub-id pub-id-type='doi'>10.1161/STROKEAHA.108.537704</pub-id><pub-id pub-id-type='pmid'>19064767</pub-id></element-citation></ref><ref id='CR16'><label>16.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Jeerakathil</surname><given-names>T</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name><name><surname>Beiser</surname><given-names>A</given-names></name><name><surname>Massaro</surname><given-names>J</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><name><surname>D’Agostino</surname><given-names>RB</given-names></name><etal></etal></person-group><article-title>Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study</article-title><source>Stroke</source><year>2004</year><volume>35</volume><fpage>1857</fpage><lpage>61</lpage><pub-id pub-id-type='doi'>10.1161/01.STR.0000135226.53499.85</pub-id><pub-id pub-id-type='pmid'>15218158</pub-id></element-citation></ref><ref id='CR17'><label>17.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lo</surname><given-names>RY</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name></person-group><article-title>Vascular burden and Alzheimer disease pathologic progression</article-title><source>Neurology</source><year>2012</year><volume>79</volume><fpage>1349</fpage><lpage>55</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0b013e31826c1b9d</pub-id><pub-id pub-id-type='pmid'>22972646</pub-id></element-citation></ref><ref id='CR18'><label>18.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kandiah</surname><given-names>N</given-names></name><name><surname>Chander</surname><given-names>RJ</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Wen</surname><given-names>MC</given-names></name><name><surname>Cenina</surname><given-names>AR</given-names></name><name><surname>Assam</surname><given-names>PN</given-names></name></person-group><article-title>Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer’s disease</article-title><source>Eur J Neurol</source><year>2015</year><volume>22</volume><fpage>150</fpage><lpage>5</lpage><pub-id pub-id-type='doi'>10.1111/ene.12546</pub-id><pub-id pub-id-type='pmid'>25142829</pub-id></element-citation></ref><ref id='CR19'><label>19.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Prasad</surname><given-names>K</given-names></name><name><surname>Wiryasaputra</surname><given-names>L</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Kandiah</surname><given-names>N</given-names></name></person-group><article-title>White matter disease independently predicts progression from mild cognitive impairment to Alzheimer’s disease in a clinic cohort</article-title><source>Dement Geriatr Cogn Disord</source><year>2011</year><volume>31</volume><fpage>431</fpage><lpage>4</lpage><pub-id pub-id-type='doi'>10.1159/000330019</pub-id><pub-id pub-id-type='pmid'>21757908</pub-id></element-citation></ref><ref id='CR20'><label>20.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>44</lpage><pub-id pub-id-type='doi'>10.1212/WNL.34.7.939</pub-id><pub-id pub-id-type='pmid'>6610841</pub-id></element-citation></ref><ref id='CR21'><label>21.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Yip</surname><given-names>PK</given-names></name><name><surname>Shyu</surname><given-names>YI</given-names></name><name><surname>Liu</surname><given-names>SI</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Chou</surname><given-names>CF</given-names></name><name><surname>Chen</surname><given-names>RC</given-names></name></person-group><article-title>An epidemiological survey of dementia among elderly in an urban district of Taipei</article-title><source>Acta Neurol Sin</source><year>1992</year><volume>1</volume><fpage>347</fpage><lpage>54</lpage></element-citation></ref><ref id='CR22'><label>22.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Shyu</surname><given-names>YI</given-names></name><name><surname>Yip</surname><given-names>PK</given-names></name></person-group><article-title>Factor structure and explanatory variables of the Mini-Mental State Examination (MMSE) for elderly persons in Taiwan</article-title><source>J Formos Med Assoc</source><year>2001</year><volume>100</volume><fpage>676</fpage><lpage>83</lpage><pub-id pub-id-type='pmid'>11760373</pub-id></element-citation></ref><ref id='CR23'><label>23.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Leys</surname><given-names>D</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Huglo</surname><given-names>D</given-names></name><name><surname>Weinstein</surname><given-names>HC</given-names></name><name><surname>Vermersch</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1992</year><volume>55</volume><fpage>967</fpage><lpage>72</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.55.10.967</pub-id><pub-id pub-id-type='pmid'>1431963</pub-id></element-citation></ref><ref id='CR24'><label>24.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Fazekas</surname><given-names>F</given-names></name><name><surname>Chawluk</surname><given-names>JB</given-names></name><name><surname>Alavi</surname><given-names>A</given-names></name><name><surname>Hurtig</surname><given-names>HI</given-names></name><name><surname>Zimmerman</surname><given-names>RA</given-names></name></person-group><article-title>MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging</article-title><source>AJR Am J Roentgenol</source><year>1987</year><volume>149</volume><fpage>351</fpage><lpage>6</lpage><pub-id pub-id-type='doi'>10.2214/ajr.149.2.351</pub-id><pub-id pub-id-type='pmid'>3496763</pub-id></element-citation></ref><ref id='CR25'><label>25.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Duara</surname><given-names>R</given-names></name><name><surname>Loewenstein</surname><given-names>DA</given-names></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Barker</surname><given-names>W</given-names></name><name><surname>Varon</surname><given-names>D</given-names></name><name><surname>Greig</surname><given-names>MT</given-names></name><etal></etal></person-group><article-title>The utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer’s disease. MCI and cognitively normal elderly subjects</article-title><source>Front Aging Neurosci</source><year>2013</year><volume>5</volume><fpage>47</fpage><pub-id pub-id-type='doi'>10.3389/fnagi.2013.00047</pub-id><pub-id pub-id-type='pmid'>24065917</pub-id></element-citation></ref><ref id='CR26'><label>26.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Duara</surname><given-names>R</given-names></name><name><surname>Loewenstein</surname><given-names>DA</given-names></name><name><surname>Potter</surname><given-names>E</given-names></name><name><surname>Appel</surname><given-names>J</given-names></name><name><surname>Greig</surname><given-names>MT</given-names></name><name><surname>Urs</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease</article-title><source>Neurology</source><year>2008</year><volume>71</volume><fpage>1986</fpage><lpage>92</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000336925.79704.9f</pub-id><pub-id pub-id-type='pmid'>19064880</pub-id></element-citation></ref><ref id='CR27'><label>27.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Radanovic</surname><given-names>M</given-names></name><name><surname>Pereira</surname><given-names>FR</given-names></name><name><surname>Stella</surname><given-names>F</given-names></name><name><surname>Aprahamian</surname><given-names>I</given-names></name><name><surname>Ferreira</surname><given-names>LK</given-names></name><name><surname>Forlenza</surname><given-names>OV</given-names></name><etal></etal></person-group><article-title>White matter abnormalities associated with Alzheimer’s disease and mild cognitive impairment: a critical review of MRI studies</article-title><source>Expert Rev Neurother</source><year>2013</year><volume>13</volume><fpage>483</fpage><lpage>93</lpage><pub-id pub-id-type='doi'>10.1586/ern.13.45</pub-id><pub-id pub-id-type='pmid'>23621306</pub-id></element-citation></ref><ref id='CR28'><label>28.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Behl</surname><given-names>P</given-names></name><name><surname>Bocti</surname><given-names>C</given-names></name><name><surname>Swartz</surname><given-names>RH</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Sahlas</surname><given-names>DJ</given-names></name><name><surname>Lanctot</surname><given-names>KL</given-names></name><etal></etal></person-group><article-title>Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients</article-title><source>Arch Neurol</source><year>2007</year><volume>64</volume><fpage>266</fpage><lpage>72</lpage><pub-id pub-id-type='doi'>10.1001/archneur.64.2.266</pub-id><pub-id pub-id-type='pmid'>17296844</pub-id></element-citation></ref><ref id='CR29'><label>29.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Yoshita</surname><given-names>M</given-names></name><name><surname>Fletcher</surname><given-names>E</given-names></name><name><surname>Harvey</surname><given-names>D</given-names></name><name><surname>Ortega</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>O</given-names></name><name><surname>Mungas</surname><given-names>DM</given-names></name><etal></etal></person-group><article-title>Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD</article-title><source>Neurology</source><year>2006</year><volume>67</volume><fpage>2192</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000249119.95747.1f</pub-id><pub-id pub-id-type='pmid'>17190943</pub-id></element-citation></ref><ref id='CR30'><label>30.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>van Straaten</surname><given-names>EC</given-names></name><name><surname>Harvey</surname><given-names>D</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Thal</surname><given-names>LJ</given-names></name><etal></etal></person-group><article-title>Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia</article-title><source>J Neurol</source><year>2008</year><volume>255</volume><fpage>1302</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1007/s00415-008-0874-y</pub-id><pub-id pub-id-type='pmid'>18825439</pub-id></element-citation></ref><ref id='CR31'><label>31.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Murray</surname><given-names>AD</given-names></name><name><surname>Staff</surname><given-names>RT</given-names></name><name><surname>Shenkin</surname><given-names>SD</given-names></name><name><surname>Deary</surname><given-names>IJ</given-names></name><name><surname>Starr</surname><given-names>JM</given-names></name><name><surname>Whalley</surname><given-names>LT</given-names></name></person-group><article-title>Brain white matter hyperintensities: relative importance of vascular risk factor in non-demented elderly patients</article-title><source>Radiology</source><year>2005</year><volume>237</volume><fpage>251</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1148/radiol.2371041496</pub-id><pub-id pub-id-type='pmid'>16126931</pub-id></element-citation></ref><ref id='CR32'><label>32.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Yun</surname><given-names>CH</given-names></name><name><surname>Thomas</surname><given-names>RJ</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Seo</surname><given-names>HS</given-names></name><name><surname>Cho</surname><given-names>ER</given-names></name><etal></etal></person-group><article-title>Obstructive sleep apnea as a risk factor for cerebral white matter change in a middle-aged and older general population</article-title><source>Sleep</source><year>2013</year><volume>36</volume><fpage>709</fpage><lpage>15</lpage><pub-id pub-id-type='pmid'>23633753</pub-id></element-citation></ref><ref id='CR33'><label>33.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Karp</surname><given-names>A</given-names></name><name><surname>Kareholt</surname><given-names>I</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Bellander</surname><given-names>T</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name></person-group><article-title>Relation of education and occupation-based socioeconomic status to incident Alzheimer’s disease</article-title><source>Am J Epidemiol</source><year>2004</year><volume>159</volume><fpage>175</fpage><lpage>83</lpage><pub-id pub-id-type='doi'>10.1093/aje/kwh018</pub-id><pub-id pub-id-type='pmid'>14718220</pub-id></element-citation></ref><ref id='CR34'><label>34.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Sattler</surname><given-names>C</given-names></name><name><surname>Toro</surname><given-names>P</given-names></name><name><surname>Schonknecht</surname><given-names>P</given-names></name><name><surname>Schroder</surname><given-names>J</given-names></name></person-group><article-title>Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer’s disease</article-title><source>Psychiatry Res</source><year>2012</year><volume>196</volume><fpage>90</fpage><lpage>5</lpage><pub-id pub-id-type='doi'>10.1016/j.psychres.2011.11.012</pub-id><pub-id pub-id-type='pmid'>22390831</pub-id></element-citation></ref><ref id='CR35'><label>35.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Stern</surname><given-names>Y</given-names></name></person-group><article-title>Cognitive reserve and Alzheimer disease</article-title><source>Alzheimer Dis Assoc Disord</source><year>2006</year><volume>20</volume><fpage>S69</fpage><lpage>74</lpage><pub-id pub-id-type='doi'>10.1097/00002093-200607001-00010</pub-id><pub-id pub-id-type='pmid'>16917199</pub-id></element-citation></ref><ref id='CR36'><label>36.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Stern</surname><given-names>Y</given-names></name><name><surname>Alexander</surname><given-names>GE</given-names></name><name><surname>Prohovnik</surname><given-names>I</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name></person-group><article-title>Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer’s disease</article-title><source>Ann Neurol</source><year>1992</year><volume>32</volume><fpage>371</fpage><lpage>5</lpage><pub-id pub-id-type='doi'>10.1002/ana.410320311</pub-id><pub-id pub-id-type='pmid'>1416806</pub-id></element-citation></ref><ref id='CR37'><label>37.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Chiu</surname><given-names>MJ</given-names></name><name><surname>Chen</surname><given-names>YF</given-names></name><name><surname>Chen</surname><given-names>TF</given-names></name><name><surname>Yang</surname><given-names>SY</given-names></name><name><surname>Yang</surname><given-names>FP</given-names></name><name><surname>Tseng</surname><given-names>TW</given-names></name><etal></etal></person-group><article-title>Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer’s disease</article-title><source>Hum Brain Mapp</source><year>2014</year><volume>35</volume><fpage>3132</fpage><lpage>42</lpage><pub-id pub-id-type='doi'>10.1002/hbm.22390</pub-id><pub-id pub-id-type='pmid'>24129926</pub-id></element-citation></ref><ref id='CR38'><label>38.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>van Straaten</surname><given-names>EC</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name><name><surname>Rostrup</surname><given-names>E</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Pantoni</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study</article-title><source>Stroke</source><year>2006</year><volume>37</volume><fpage>836</fpage><lpage>40</lpage><pub-id pub-id-type='doi'>10.1161/01.STR.0000202585.26325.74</pub-id><pub-id pub-id-type='pmid'>16439704</pub-id></element-citation></ref></ref-list></back></article></PAPER>